Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells

被引:69
作者
Bose, D. [1 ,2 ]
Zimmerman, L. J. [3 ]
Pierobon, M. [4 ]
Petricoin, E. [4 ]
Tozzi, F. [2 ]
Parikh, A. [3 ]
Fan, F. [2 ]
Dallas, N. [1 ,2 ]
Xia, L. [2 ]
Gaur, P. [1 ,2 ]
Samuel, S. [2 ]
Liebler, D. C. [3 ]
Ellis, L. M. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77230 USA
[3] Vanderbilt Univ, Jim Ayers Inst Precanc Detect & Diag, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
[4] George Mason Univ, Ctr Appl Prote & Mol Med, Fairfax, VA 22030 USA
关键词
chemoresistance; colorectal cancer; chemotherapy; conditioned medium; cancer stem cells; GRANULIN-EPITHELIN PRECURSOR; OXALIPLATIN-BASED CHEMOTHERAPY; LEUKOCYTE PROTEASE INHIBITOR; SIGNALING ANALYSIS; SIDE-POPULATION; OVARIAN-CANCER; COLON; PROGRANULIN; BEVACIZUMAB; ACTIVATION;
D O I
10.1038/bjc.2011.449
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND: Recent studies suggest that cancer stem cells (CSCs) mediate chemoresistance, but interestingly, only a small percentage of cells in a resistant tumour are CSCs; this suggests that non-CSCs survive by other means. We hypothesised that chemoresistant colorectal cancer (CRC) cells generate soluble factors that enhance survival of chemonaive tumour cells. METHODS: Chemoresistant CRC cells were generated by serial passage in oxaliplatin (Ox cells). Conditioned media (CM) was collected from parental and oxaliplatin-resistant (OxR) cells. CRC cells were treated with CM and growth and survival were assessed. Tumour growth rates were determined in nude mice after cells were treated with CM. Mass spectrometry (MS) identified proteins in CM. Reverse phase protein microarray assays determined signalling effects of CM in parental cells. RESULTS: Oxaliplatin-resistant CM increased survival of chemo-naive cells. CSC CM also increased growth of parental cells. Parental and OxR mixed tumours grew larger than tumours composed of parental or OxR cells alone. Mass spectrometry detected unique survival-promoting factors in OxR CM compared with parental CM. Cells treated with OxR CM demonstrated early phosphorylation of EGFR and MEK1, with later upregulation of total Akt. We identified progranulin as a potential mediator of chemoresistance. CONCLUSION: Chemoresistant tumour cells and CSCs may promote resistance through soluble factors that mediate survival in otherwise chemosensitive tumour cells. British Journal of Cancer (2011) 105, 1759-1767. doi:10.1038/bjc.2011.449 www.bjcancer.com
引用
收藏
页码:1759 / 1767
页数:9
相关论文
共 56 条
[1]
Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models [J].
Arumugam, Thiruvengadam ;
Ramachandran, Vijaya ;
Logsdon, Craig D. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (24) :1806-1818
[2]
Crypt stem cells as the cells-of-origin of intestinal cancer [J].
Barker, Nick ;
Ridgway, Rachel A. ;
van Es, Johan H. ;
van de Wetering, Marc ;
Begthel, Harry ;
van den Born, Maaike ;
Danenberg, Esther ;
Clarke, Alan R. ;
Sansom, Owen J. ;
Clevers, Hans .
NATURE, 2009, 457 (7229) :608-U119
[3]
Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer [J].
Beatty, Gregory L. ;
Giantonio, Bruce J. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) :683-688
[4]
Role of Pharmacogenetics as Predictive Biomarkers of Response and/or Toxicity in the Treatment of Colorectal Cancer [J].
Bhushan, Shriya ;
McLeod, Howard ;
Walko, Christine M. .
CLINICAL COLORECTAL CANCER, 2009, 8 (01) :15-21
[5]
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases [J].
Blazer, Dan G., III ;
Kishi, Yoji ;
Maru, Dipen M. ;
Kopetz, Scott ;
Chun, Yun Shin ;
Overman, Michael J. ;
Fogelman, David ;
Eng, Cathy ;
Chang, David Z. ;
Wang, Huamin ;
Zorzi, Daria ;
Ribero, Dario ;
Ellis, Lee M. ;
Glover, Katrina Y. ;
Wolff, Robert A. ;
Curley, Steven A. ;
Abdalla, Eddie K. ;
Vauthey, Jean-Nicolas .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5344-5351
[6]
Recent advances in cancer stem cells [J].
Cho, Robert W. ;
Clarke, Michael F. .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2008, 18 (01) :48-53
[7]
Expression of Progranulin (Acrogranin/PCDGF/Granulin-Epithelin Precursor) in Benign and Malignant Ovarian Tumors and Activation of MAPK Signaling in Ovarian Cancer Cell Line [J].
Cuevas-Antonio, R. ;
Cancino, C. ;
Arechavaleta-Velasco, F. ;
Andrade, A. ;
Barron, L. ;
Estrada, I. ;
Fernandez, R. L. ;
Olguin, V. ;
Ruiz, S. ;
Imani, F. ;
Zeferino-Toquero, M. ;
Ulloa-Aguirre, A. ;
Gerton, G. L. ;
Diaz-Cueto, L. .
CANCER INVESTIGATION, 2010, 28 (05) :452-458
[8]
Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition [J].
Dallas, Nikolaos A. ;
Xia, Ling ;
Fan, Fan ;
Gray, Michael J. ;
Gaur, Puja ;
van Buren, George, II ;
Samuel, Shaija ;
Kim, Michael P. ;
Lim, Sherry J. ;
Ellis, Lee M. .
CANCER RESEARCH, 2009, 69 (05) :1951-1957
[9]
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells [J].
Devoogdt, N ;
Ghassabeh, GH ;
Zhang, J ;
Brys, L ;
De Baetselier, P ;
Revets, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5778-5782
[10]
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 [J].
Dy, Grace K. ;
Hobday, Timothy J. ;
Nelson, Garth ;
Windschitl, Harold E. ;
O'Connell, Michael J. ;
Alberts, Steven R. ;
Goldberg, Richard M. ;
Nikcevich, Daniel A. ;
Sargent, Daniel J. .
CLINICAL COLORECTAL CANCER, 2009, 8 (02) :88-93